IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Baltimore, et al.

Serial No: To be assigned

Filed:

January 4, 2002

For:

Nuclear Factors Associated with

Transcriptional Regulation

Attorney Docket No.

APBI-P05-035

Art Unit:

To be assigned

Examiner:

To be assigned

Assistant Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please enter the following amendment:

In the specification:

Please replace the only complete paragraph under the heading <u>Related</u>

<u>Applications</u> on page 1 with the following text:

This application is a continuation of Serial No. 08/464,364, filed June 5, 1995, which is a divisional of Serial No. 08/418,266, filed April 6, 1995, which is a continuation of 07/791,898, filed November 13, 1991, which is a continuation-in-part of application of Serial No. 06/946,365 (WHI86-10), filed December 24, 1986, and of Serial No. 07/318,901 (WHI87-11A), filed March 3, 1989, and of Serial No. 07/162,680 (WHI87-11), filed March 1, 1988, and of Serial No. 07/341,436 (WHI89-02) filed April 21, 1989, and of Serial No. 06/817/441 (MIT-4167), filed January 9, 1986, and of Serial No. 07/155,207 (MIT-4167A), filed February 12, 1988, and of Serial No. 07/280,173 (MIT-4167AA), filed December 5, 1988. The contents of the ten referenced applications are incorporated herein by reference.

The replacement paragraph presented above incorporates changes as indicated by the marked-up version below.

This application is a continuation of Serial No. 08/464,364, filed June 5, 1995, which is a divisional of Serial No. 08/418,266, filed April 6, 1995, which is a continuation of 07/791,898, filed November 13, 1991, which is a continuation-in-part of application of Serial No. 06/946,365 (WHI86-10), filed December 24, 1986; and of Serial No. 07/318,901 (WHI87-11A), filed March 3, 1989; and of Serial No. 07/162,680 (WHI87-11), filed March 1, 1988; and of Serial No. 07/341,436 (WHI89-02) filed April 21, 1989; and of Serial No. 06/817/441 (MIT-4167), filed January 9, 1986; and of Serial No. 07/155,207 (MIT-4167A), filed February 12, 1988, and of Serial No. 07/280,173 (MIT-4167AA), filed December 5, 1988. The contents of the seven ten referenced applications are incorporated herein by reference.

Although Applicant believes no fees are needed in connection with filing this Preliminary Amendment, should fees be due in connection with the filing of this Amendment, please charge the fees to our **Deposit Account No. 18-1945.** If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit account.

Date: January 4, 2002

Customer No: 28120
Docketing Specialist
Ropes & Gray
One International Place
Boston, MA 02110
Phone: 617-951-7739

Fax: 617-951-7050

Respectfully Submitted,

Matthew P. Vincer Reg. No. 36,709

TRANSMITTAL OF FORMAL DRAWINGS

Docket No APBI-P05-035

In Re Application Of: Baltimore, et al.

Serial No.	Filing Date	Batch No.	Examiner	Art Unit
To be assigned	Herewith	To be assigned	To be assigned	To be assigned

Invention:

Nuclear Factors Associated with Transcriptional Regulation

Address to Assistant Commissioner for Patents Washington, D.C. 20231

Transmitted herewith are:

58 sheets of formal drawing(s) for this application.

Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawing.

Signature

Matthew P. Vincent

Registration No. 36,709

Ropes & Gray

Patent Group

One International Place

Boston, MA 02110

Customer ID 28120

Dated: January 4, 2002




Fig. 1A




Fig. 1B




Fig. 1C



Fig. 2A

1 2

F —

HeLa

Fig. 2B




Fig. 4A





Fig. 4B






Fig. 5B




Fig. 6




Fig. 7




Fig. 8




Figure 9B

Figure 10A





Figure 10B






Fig. 10C




Figure 10E




Figure 11A



Figure 11B









Fig. 11C










Figure 13C

Extract EW/c 1 μL Fragment Comp




Figure 13D







Figure 14





	Cov		22
2	K 3 KBIS	ct)	t t
	KZ		2
	N3 (2770		28
	$egin{array}{c} K\mathfrak{Z} \\ K\mathfrak{Z} \\ K\mathfrak{Z} \\ K\mathfrak{Z} \end{array} \} 8559$	1 0	18 19
	(~	1 1	<u>8</u>
	KS MPCII		17
	(EX	110	9
	KS EW		75
	(EX	1 1	$-\frac{5}{4}$
p	ela { S X	1 1	13
156	K3 \	1	12
FIGURE	$KS \left\{ \begin{array}{c} KS \\ KS \end{array} \right\}$ WEHI	1 1	10 11 12 13 14 15 16 17
SUR		1	
F16	K2 \ \ 707	1 0	
	K3	0	8
69	$\begin{array}{c} KS \\ KS \\ KZ \end{array} \right\} 28B9$	1 0	7
			9
	KS. } PD	1 0	2
	$egin{array}{c} \mathcal{K}\mathcal{S} \\ \mathcal{K}\mathcal{K}\mathcal{S} \\ \mathcal{K}\mathcal{K}\mathcal{S} \\ \mathcal{K}\mathcal{K}\mathcal{S} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal{K}\mathcal{K}\mathcal{K}\mathcal{K} \\ \mathcal$	111	4
	KS }	1	2
	K3 \ EM	**	2
	_ { £ X	1	
	.		
	Extract Probe		
	Extrac		
	ш С		



MHC mhc1	TGGGGATTCCCCA TGcGGATTCCCaA
к EN к en	aGGGGACTttCCg aaattAcTttCCg a
SVEN HIV	TGGGGAcTttCCA TGGGGAcTttCCA aaGGGAcTttCCg

Fig. 17




Fig. 18A




Fig. 18A (CONTINUED)




Fig. 18A (CONTINUED)




Fig. 18B




Fig. 18C




Fig. 19

n helix	IEKEVIRV <u>WE</u> C <u>N</u> R <u>R</u> QKEKRINPC *	TPLQVRV <u>WE</u> INKRMRSK *	SRIQIKNWVSNRRRKEKTIT *	IPEKNVRI <u>WE</u> ONRBAKLRKKO *	<u>-</u> Smrviqu <u>weqn</u> r <u>r</u> skerrlk *
helix turn helix	RRKK <u>R</u> TSIETNVRFA <u>L</u> EKSFLANQKPTSEEILLIAEQLHMEKEVIRV <u>WECNRR</u> QKEKRINPC *	SPKGKSSISPQARAFLEQVFRRKQSLNSKEKEEVAKKCGITPLQVRVWEINKRMRSK * * *	KPYRGHRFTKENVRILESWFAKNPYLDTKGLENLMKNTSLSRIQIKNWVSNRRRKEKTIT *	QRPKRTRAKGEALDVLKRKFEINPTPSLVERKKISDLIGMPEKNVRIWEQNRRAKLRKKQ * *	RRGP <u>R</u> TTIKQN Q LDV <u>L</u> NEMFSNTPKPSKHARAKLALETG <u>L</u> SMRVIQV <u>WEQN</u> RRSKERRLK * * *
	Oct-2	al	α2	pho2	mec-3

voo:	KST	KEN	(conserved residues in homeo-box family)
itn <u>we</u> h <u>nhr</u> mrlk *	IKIWEONKBAKIK *	iki <u>we</u> onrrmkw *	WE N B
LANELGLATRT:	LSSELGINEAQ:	IAHALC <u>L</u> TERQ	н
ALRIAEALDPYPNVGTIEFLANELGLATRTITNWEHNHRMRLKQQV	EKRPRTAFSSEQLARIKREFNENRYLTERRRQQLSSELGINEAQIKIWEQNKRAKIKKST *	RKRGBOTYTRYQTLELEKEFHFNRYLTRRRIEIAHALCLTERQIKIWEONREMKWKKEN *	н
a <u>l</u> re	RLKR	ELEK	н
SEEQKE	SSEQLA	TRYQTL	a
SKKQ <u>R</u> VLFSEE Q KE	EKRPRTAF	RKRGBQTY	μą
cut	en	Antp	

Fig. 20




Figure 21B




Figure 22A




Figure 22B




Figure 23A





Figure 23B







Figure 24C






Fig. 25





Fig. 26A



Treatment: none

CONTROL TPA

Fraction: N C P N C P

1 2 3 4 5 6

κB-Probe: wt

Fig. 27A

Treatment: Dissociating Agents
CONTROL TPA

Fraction: N C P N C P

κB-Probe:

Fig. 27B

wt




Fig. 27C




Fig. 28




Fig. 29




Fig. 30




Fig. 31A





Fig. 31B



46/58

Fig. 32




Fig. 33




Fig. 34A





Fig. 34B








Fig. 35C








Fig. 37A




Fig. 37B




Fig. 38A




Fig. 38B






Fig. 39









Fig. 42A



70Z/3

PMA LPS V

0 6 12 20 0 6 12 20 0 6 12 20

-κ

1 2 3 4 5 6 7 8 9 10 11 12

Fig. 42C

Figure 43

GAGTGAGCAGTAGGATGTGGAGCTCAAAGCAGAGTTGCACCTGCTGACCCCCCAGCCTGAATTTGGTTCACCCAGAG GCACAGTGGGGAAGGCTGGACAGAAGAAGAAGGAACGATCCATAGAGATGTGAACCAGAATCAGTCGTGTTGAGC TCTGGGTATATCACTACATGTTTAACTCTTGCAAGACCGTTTGCCCAGGGCTTTGGTACCACAGGGGTTAGAGTTAC TGAACCTCCCCCTCCCCAACGCCCTGGCATTTGCAATTAAAACTGGGATTCAAGGGCCAAATTCAAGCCCA ACTACAAGTCAGAAAGGCATGTTTAGAAAGAGGCATGCTAAGGACTGATGGTGGAACGGCCAATTTGTCCCCACCA CCCCACAACAGGATCGGCACCCCAGAGTTCAACAAGTGGCTGACTTTGTTAAAACACTACGTGGGAACCCATAGTC CCGGATCAGTAGTTGCACAGCCCCCTCCCCGACAGACTACACCGCTGTTTGCTGATCCTTGCCCACCCCATGCTCT CCTCCCAGGCCCCCGTTCTGCTCCTGTCCTGCGGCGCTGGATTGAACCGCACACAAGTCTGCATCTGGCACGAA TTCTCATGGGAGCCACGTCATGAGGTACGTGGTTGCACCCTATCACAAGAAGTCTTGCAGTTCTGACTCTCCTGA GCTCGGTGGGAAAGTCTGGATAGTACCTCCCCTCTCCTGCCACAAAAGCAGCCCTCACATTCACAAGTTTCCAAAAG CAGGTCTATTGAGTTTCTCTTCAGAGCGAGCCTTTGTCAAACACACCTGGAGGGGGGGAGTCTCACCTCTCCCCAGC AACTCAGATCAGTGCCTTATTTTAATGCTCCGGCCCAATCCTGAGGTGCTGCTGGGTTTTGTGGGCTGCGTTTTTGT AACATTGCAACCTTATAAAAATTAACTATTTCGACAATGCCGCAGAAGGAAATTCTGTGTTTAGGTGCTGGTGG × Д AAGGGGGGGGAAGGGGGGGGTCCTTGGTTCATTTCCCTTCACTGTGTGACCGAAGTTTTGCTTTTATTTGTAAACA Ц 回 ر ا 二 H ഗ Ĺц ഗ IJ G

TCTTGAATTACCCGTCGTTTTCCAGTCTTCATCGTGCTGTTGTCAGGCCACTGGAGGGAATTCCCCGTCTCGGAAC H U H ᆸ R P > > Ø 田 Н ഗ ഗ

Figure 43 (continued)

GAGCCGCCCGCCGTGGAGGGCTGCGAGCCGCCGCGCAAGGAACGGCAAGGCCGGGCTGCTGCCGCCCGACGACCGCC Н Н ᠐ ᠐ Ø X ഥ × ፈ വ Ы ນ ຫ 口 闰 ፚ E Y R Q L V 면 면 노 Σ L D S GCCCCGCGAGCCGCCCGCCCGCCGCCTGGGCCCAGCACGCTCACCGAGGACGGCGACACTTTTCTCCACTTG ᆸ Q L T E D G D A Q Z Ø 二 Д Ø GCGATCATTCACGAGGAAAAGGCCCTGAGCCTGGAGGTGATCCGGCAGGCCGCTGGGGACGCCGCTTCCTGAACT Ø ø Ω ტ A Ø N O Н ы > S ᆸ K A 田

TCCAGAACAACCTCAGCCAGACTCCGCTCCACCTGGCGGTGATCACGGACCAGGCCGAAATCGCCGAGCACTGCT A E T D Q Ank. II N L S Q T P L H L A V I

GAAGGCTGGCTGCGACCTGGATGTCAGGGACTTCCGTGGGAACACCCCCGCTCCACATCGCCTGCCAGCAGGGCTCG Ø D A T P L H I A Ank. F R G N Ω ĸ D V

CTCCGCAGCGTCAGGCTGCCAGCAGCAGCCCCCCCACCTCCTCGCCGTCCTGCAGGCCAACTACA Ø Õ L L A V L H 耳 വ Ø ОНО L S S ACGGCCATACATGTCTCCATTTGGCATCTATTCAAGGATACCTGGCTGTTGTCGAATACCTGCTGTCCTTAGGAGC L L S [교] A V V L A S I Q G Y L 二 ᆸ

Ank. IV

AGATGTAAATGCTCAGGAGCCATGCAATGGGAGAACAGCACTACACTTGGCCGTAGACCTTCAGAACTCAGACCTG ᆡ니 Z H A V 口 Ή H Ø ⊱⊣ Q

Figure 43 (continued)

 \geq GTGTCACTTCTGGTGAAACACGGGCCAGATGTGAACAAAGTGACCTACCAGGGCTACTCCCCATACCAGGCTTACAT U Ø × ⊱ > X Z > Ω Д ტ H × L V ᆸ ഗ

GGGCAGAGACAACGCCAGCATACAGGAGCAGCTGAAGCTGCTGACCACAGCTGACCTGCAGATACTGCCGAAAGT 354 S ഗ

GTGCCCTGCTCCCTGACCCTGGCTGCTCAGGGTTGAGGAGTCCGACCATGGGAGAGGTGACCTGGCTGCTGGGAGG ACATCATGCTAACAGGTTCCATGCTCTGACCTGTACTTAAGTAACGGGATGGGATGTAACATCATCATAAGAGATC GAAGACAGCTGACATTTTAAAGCAGAGGTTTCTGTGAGAAGTGACTGTGTACATATGTATAGGAAAAAAAGCCTGA AGTGAACATGCACCCATCTGATAAAGAGCCACGTTATCTAATTTTCTCTGCCACATGAGGATAACGGACTGCACGT CCAATGTGCTGTTGTCAGAAATGCGTTTGAGAGCTGCCTTGTGACACTAAGTGCTGTGAGGAGTGCTCATCCCCCT CGGTGGCAAGACAGGCTTGCACAAACGTCCCATCTGCTTGAAGACTGTGAGGTTGGCATTAGGTTGAGGCACTGCT TTTAGCAACTGTATAGAATGTAAATACTGTACATCTTTGTTTATAATTATTTTGGTACCTGTGAGATATGTATTTA ITAAAAAAGGCAGATTTCTGTAAAAAA